Merck Sharp & Dohme’s Keytruda has been approved in Europe for metastatic urothelial carcinoma, a move which helps it catch up with its immunotherapy rivals.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
